skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.10e (Release date: 2017-10-30)
SearchBox Top
SearchBox Bottom
Yttrium Y-90 Ibritumomab Tiuxetan (Code C1812)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Yttrium Y-90 Ibritumomab Tiuxetan

Definition: A radioimmunotherapeutic agent consisting of a murine monoclonal anti-CD20 antibody (ibritumomab) linked by the chelator tiuxetan to the radioisotope yttrium-90 (Y 90). Yttrium Y 90 ibritumomab tiuxetan binds to and specifically delivers beta radiation to CD20-expressing tumor cells, thereby minimizing the systemic effects of radiation.

NCI-GLOSS Definition: A radiolabeled monoclonal antibody that is used to treat certain types of B-cell non-Hodgkin lymphoma and is being studied in the treatment of other types of B-cell tumors. It is made up of the monoclonal antibody ibritumomab plus the radioisotope yttrium Y 90. It binds to the protein called CD20, which is found on B cells. The radiation in the yttrium Y 90 may kill the cancer cells. Y 90 ibritumomab tiuxetan is a type of radiopharmaceutical.

Display Name: Yttrium Y-90 Ibritumomab Tiuxetan

Label: Yttrium Y-90 Ibritumomab Tiuxetan

NCI Thesaurus Code: C1812 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C0879283  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
IDEC-Y2B8 monoclonal antibody
Y 90 ibritumomab tiuxetan
Y 90 Ibritumomab Tiuxetan
Y 90 Zevalin
Yttrium Y 90 Ibritumomab Tiuxetan
Yttrium Y-90 Ibritumomab Tiuxetan
yttrium Y90 ibritumomab tiuxetan

External Source Codes: 
NSC Code 710085 (see NCI DTP info)
PDQ Closed Trial Search ID 38483
PDQ Open Trial Search ID 38483 (check for NCI PDQ open clinical trial info)
UMLS CUI C0879283

Other Properties:
     Name Value (qualifiers indented underneath)
Accepted_Therapeutic_Use_For Non-Hodgkin's Lymphoma
code C1812
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Y_90_Ibritumomab_Tiuxetan
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: Yes  


Mainbox Bottom